Boardroom Alpha
Meeting calendar
CCAP · Annual meeting · Friday, May 15, 2026

Crescent Capital Bdc Inc

2 nominees · 2 ballot items.

Elect two Class II Directors (Susan Yun Lee and Michael S. Segal) to three-year terms and ratify Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Market cap
$407M
1Y TSR
-13.8%
Board grade
B-
Record date
Mar 18, 2026
Filing
DEF 14A
Meeting concluded · May 15, 2026

Follow how the vote landed and what changed on Crescent Capital Bdc Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot2

  1. 1

    Election of Class II Directors

    ManagementBoard: FOR

    Re-elect Susan Yun Lee and Michael S. Segal as Class II Directors, each to serve a three-year term expiring at the 2029 annual meeting of stockholders.

  2. 2

    Ratification of Ernst & Young LLP as Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the Audit Committee and Board’s selection of Ernst & Young LLP as the Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Director elections

Nominees on the ballot2

Independent
Tenure on this board
4.0 yrs
Also a director at
American Battery Technology Co (ABAT)
Ownership

Top institutional holders10

Latest 13F quarter
1Texas County District Retirement System13.6%5,001,752$61M
2Blackstone Inc.11.4%4,205,307$51M
3Fidelity National Financial, Inc.11.4%4,205,307$51M
4SUN LIFE FINANCIAL INC6.0%2,226,308$27M
5Invesco Ltd.2.7%989,805$12M
6ARES MANAGEMENT LLC1.5%546,409$7M
7Mariner, LLC1.3%463,365$6M
8Bulldog Investors, LLPActivist1.2%456,955$6M
9Focus Partners Wealth1.0%367,585$4M
10Almitas Capital LLC1.0%356,905$4M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Crescent Capital Bdc Inc 2026 annual meeting?
Crescent Capital Bdc Inc (CCAP) holds its 2026 annual shareholder meeting on Friday, May 15, 2026.
What is the record date for the Crescent Capital Bdc Inc 2026 meeting?
The record date for the Crescent Capital Bdc Inc 2026 meeting is Wednesday, March 18, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Crescent Capital Bdc Inc's 2026 meeting?
The board is presenting 2 director nominees at the Crescent Capital Bdc Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Crescent Capital Bdc Inc 2026 meeting?
Shareholders will vote on 2 proposals at the Crescent Capital Bdc Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer